Myomo, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the three and nine months ended September 30, 2026, disclosing revenue growth alongside a widening accumulated deficit and reduced cash position.

Key Highlights

  • Quarterly revenue of $12,330,517 for the three months ended September 30, 2026, up from $10,090,699 in the same period of 2025, according to the filing.
  • Nine-month revenue reached $34,148,370 for the period ended September 30, 2026, compared to $29,574,746 for the nine months ended September 30, 2025.
  • Accumulated deficit of $129,951,940 as of September 30, 2026, increased from $118,688,422 at December 31, 2025.
  • Cash and cash equivalents of $11,099,159 as of September 30, 2026, down from $14,132,027 at December 31, 2025.
  • Total stockholders' equity fell to $2,750,692 from $11,403,467 at December 31, 2025.
  • 40,099,174 shares of common stock outstanding as of November 3, 2026, per the filing cover page.
  • Warrant derivative liability of $1,772,084 as of September 30, 2026, up from $999,418 at December 31, 2025.

Myomo Reports Third-Quarter 2026 Financial Results and Balance Sheet Position

According to the filing, Myomo, Inc. (NYSE American:MYO) reported revenue of $12,330,517 for the three months ended September 30, 2026, an increase from $10,090,699 in the comparable prior-year quarter. Gross profit for the third quarter was $8,790,094, compared to $6,442,248 for the three months ended September 30, 2025. For the nine-month period ended September 30, 2026, the company disclosed revenue of $34,148,370 and gross profit of $24,134,249, versus $29,574,746 and $19,104,050, respectively, in the year-earlier nine-month period.

The condensed consolidated balance sheet as of September 30, 2026, showed total assets of $33,804,876, compared to $38,636,573 at December 31, 2025, the filing stated. Total liabilities increased to $31,054,184 from $27,233,106 over the same period. The company reported long-term debt, net of discount of $1,994,528, of $11,654,570 as of September 30, 2026, alongside a current portion of long-term debt, net of discount of $295,486, of $1,787,848. The warrant derivative liability rose to $1,772,084 from $999,418 at year-end 2025.

The company's accumulated deficit grew to $129,951,940 as of September 30, 2026, from $118,688,422 at December 31, 2025, the filing disclosed. Total stockholders' equity declined to $2,750,692 from $11,403,467 over the same span. Common stock outstanding was 40,047,360 shares as of September 30, 2026, with 40,047,387 shares issued. Short-term investments decreased to $847,027 from $4,261,782 at December 31, 2025. The filing noted that forward-looking statements are the company's own and are subject to the cautionary language included in the report, including risks related to reimbursement, financing, and cash flow.

What Was Disclosed

Myomo filed its Form 10-Q for the quarter ended September 30, 2026, reporting higher revenue and gross profit year-over-year while disclosing a widening accumulated deficit, lower cash balances, higher total liabilities, and reduced stockholders' equity relative to December 31, 2025.